APAC Heart Failure Devices Market Industry Trends and Forecast to 2034: Segmented by (Device, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$2.28 BnPlaceholder estimate
Estimate 2025$2.49 Bn19.4% of the global market
Projected 2034$5.51 Bn 120.8%Adds $3.01 Bn over 9 forecast years
CAGR 2025–20349.2%Faster than 43% of 173 Medical Devices markets here
Key players5
APAC is 19.43% of the global market.
Among regions, the largest is North America at $5.89 Bn.
Abbott Laboratories, Medtronic, Boston Scientific Corporation, Abiomed (Johnson & Johnson), Impulse Dynamics (see all)
Active clinical trials
10 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Heart Failure Devices Market Analysis Executive Summary
Heart failure devices help weak hearts pump or keep rhythm, including pumps, defibrillators, resynchronisation devices and sensors.
Key segments of the heart Failure Devices market include device (Ventricular Assist Devices, CRT Devices and ICDs) and use (Bridge to Transplant, Destination Therapy and Monitoring).
Asia Pacific Heart Failure Devices market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Heart Failure Devices Market Dynamics
Market Growth Drivers
Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the heart Failure Devices market.
Opportunity
Less invasive procedures, remote monitoring of implanted devices and rising access to cardiac care in emerging markets give the heart Failure Devices market room to grow.
Market Restraints
High device prices, the need for trained specialists, reimbursement pressure and product recalls hold back the heart Failure Devices market.
Competitive Landscape for Heart Failure Devices Market in APAC
The heart Failure Devices market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Heart Failure Devices Market in APAC
Heart Failure Devices in APAC: rules, payment and research
In some of the countries we cover here, medical devices are regulated by TGA (Australia)[1], NMPA (China)[2], MDACS (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], MDA (Malaysia)[6], Medsafe (WAND) (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 10 studies on Heart Failure Devices that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how heart Failure Devices products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Device
4.2 By Use
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Abbott Laboratories
7.2 Medtronic
7.3 Boston Scientific
7.4 Abiomed (Johnson & Johnson)
7.5 Impulse Dynamics
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The heart Failure Devices market can be segmented based on various criteria, including device, use and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: FDA 510(k) and PMA databases, 510(k) clearances and PMA approvals since 2015 for devices whose name has this market's words. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Heart Failure Devices right now, from free public sources.
Clinical trials
10 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Heart Failure Devices market in Asia Pacific?
Placeholder estimate: about $2.49 Bn in 2025, rising to about $5.51 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Heart Failure Devices market in Asia Pacific growing?
Placeholder estimate: about 9.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Heart Failure Devices market report cover?
The report splits the market by device (Ventricular Assist Devices, CRT Devices, ICDs, Implantable Monitors), use (Bridge to Transplant, Destination Therapy, Monitoring) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Heart Failure Devices market?
Key players include Abbott Laboratories, Medtronic, Boston Scientific Corporation, Abiomed (Johnson & Johnson) and Impulse Dynamics.
What is driving the Heart Failure Devices market?
Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the heart Failure Devices market.
How many clinical trials on Heart Failure Devices are running in Asia Pacific?
10 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Heart Failure Devices?
PubMed lists 11,276 papers on Heart Failure Devices added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
China
Canada
Japan
Germany
France
UK
Brazil
Italy
India
Spain
Ecuador
Saudi Arabia
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
Biotronik SE & Co. KG